Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 2002 Jun;36(6):1075-9.

Valganciclovir: an advance in cytomegalovirus therapeutics.

Author information

1
Department of Clinical Pharmacy, School of Pharmacy, University of California-San Francisco, USA.

Abstract

OBJECTIVE:

To review the pharmacology, pharmacokinetics, and preliminary clinical data for valganciclovir, a new oral agent for the therapy of cytomegalovirus (CMV) retinitis.

DATA SOURCES:

Relevant literature was extracted via MEDLINE/PUBMED and searchable abstracts from infectious diseases conferences covering the period from January 1990 to April 2002. Tertiary references provided background information.

DATA SYNTHESIS:

Current standard treatment for CMV retinitis consists of intravenous therapy, intraocular implant, and intraocular injection. The low bioavailability of oral ganciclovir restricts its use to prophylaxis and maintenance treatment. Oral valganciclovir, recently approved for both induction and maintenance therapy of CMV retinitis, may fill a niche for this disease.

CONCLUSIONS:

Although only 1 clinical study has been published for valganciclovir, its favorable pharmacokinetic profile, encouraging preliminary efficacy data, ease of administration, and lack of potential catheter-related complications make it a favorable option for the treatment of CMV retinitis in HIV-positive patients.

PMID:
12022911
DOI:
10.1345/aph.1A393
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center